公开(公告)号：WO2011129579A3

公开(公告)日：2012-02-02

申请号：PCT/KR2011002560

申请日：2011-04-12

Applicant: HANMI HOLDINGS CO LTD ,  JANG KI YOUNG ,  PARK MIJIN ,  KIM KYEONG SOO ,  KIM YONG IL ,  PARK JAE HYUN ,  WOO JONG SOO

Inventor： JANG KI YOUNG ,  PARK MIJIN ,  KIM KYEONG SOO ,  KIM YONG IL ,  PARK JAE HYUN ,  WOO JONG SOO

IPC: A61K9/22 ,  A61K9/16 ,  A61K31/192

CPC classification number: A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K31/192

Abstract: An oral pharmaceutical composition of the present invention comprising fenofibric acid or a pharmaceutically acceptable salt thereof, and 0.22 to 1 part by weight of an alkalifying agent based on 1 part by weight of fenofibric acid has improved bioavailability and a minimized absorption deviation in the gastrointestinal tract, which is useful in treating hyperlipidemia and hypertriglyceridemia.

Abstract translation: 包含非诺贝酸或其药学上可接受的盐的本发明的口服药物组合物和基于1重量份非诺贝酸的0.22至1重量份的碱化剂具有改善的生物利用度和最小化的胃肠道吸收偏差 ，其可用于治疗高脂血症和高甘油三酯血症。

公开(公告)号：WO2010085047A2

公开(公告)日：2010-07-29

申请号：PCT/KR2009/007829

申请日：2009-12-28

Applicant: HANMI PHARM. CO., LTD. ,  WOO, Jong Soo ,  PARK, Jae Hyun ,  KIM, Yong Il ,  KIM, Kyeong Soo ,  YIM, Ho Taek ,  IM, Ji Hyun

Inventor： WOO, Jong Soo ,  PARK, Jae Hyun ,  KIM, Yong Il ,  KIM, Kyeong Soo ,  YIM, Ho Taek ,  IM, Ji Hyun

IPC: A61K31/44 ,  A61P9/10 ,  A61P9/00

CPC classification number: A61K31/41 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2077 ,  A61K9/5084 ,  A61K31/4178 ,  A61K31/44 ,  A61K31/4422 ,  A61K2300/00

Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine and losartan as active ingredients, and a disintegrant which is a mixture of at least two components selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, and crosspovidone, which exhibits a high and stable level of amlodipine and losartan dissolution rates.

Abstract translation: 本发明涉及一种用于预防或治疗包含氨氯地平和氯沙坦作为活性成分的心血管疾病的固体药物组合物，和崩解剂，其是选自淀粉羟乙酸钠，交联羧甲基纤维素钠和交联聚维酮的至少两种组分的混合物 ，其表现出高且稳定的氨氯地平和氯沙坦溶出速率水平。

公开(公告)号：WO2008069612A1

公开(公告)日：2008-06-12

申请号：PCT/KR2007/006352

申请日：2007-12-07

Applicant: HANMI PHARM. CO., LTD. ,  WOO, Jong Soo ,  YI, Hong Gi ,  CHI, Moon Hyuk ,  KIM, Kyeong Soo

Inventor： WOO, Jong Soo ,  YI, Hong Gi ,  CHI, Moon Hyuk ,  KIM, Kyeong Soo

IPC: A61K31/44

CPC classification number: A61K31/44 ,  A61K9/2077 ,  A61K9/209 ,  A61K31/4178 ,  A61K31/4422 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical composition comprising a part containing amlodipine or a pharmaceutically acceptable salt thereof and another separate part containing losartan or a pharmaceutically acceptable salt thereof, which exhibits improved preventive and therapeutic effects against cardiovascular disorders.

Abstract translation: 本发明涉及药物组合物，其包含含有氨氯地平或其药学上可接受的盐的部分和含有氯沙坦或其药学上可接受的盐的另一部分，其对心血管疾病具有改进的预防和治疗作用。

公开(公告)号：WO2011155793A3

公开(公告)日：2012-04-26

申请号：PCT/KR2011004271

申请日：2011-06-10

Applicant: HANMI HOLDINGS CO LTD ,  KIM YONG IL ,  KIM KYEONG SOO ,  JANG KI YOUNG ,  KIM YO HAN ,  PARK JAE HYUN ,  WOO JONG SOO

Inventor： KIM YONG IL ,  KIM KYEONG SOO ,  JANG KI YOUNG ,  KIM YO HAN ,  PARK JAE HYUN ,  WOO JONG SOO

IPC: C07D401/12 ,  A61K31/497 ,  A61P35/00 ,  C07D401/14

CPC classification number: A61K47/24 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2077 ,  A61K9/4858 ,  A61K31/497 ,  A61K31/517 ,  A61K47/12 ,  C07D401/12 ,  C07D401/14

Abstract: The present invention relates to a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof, and an acidic additive. This composition, owing to improved stability even after a long-term storage, is suitable for inhibiting the growth of cancer cells.

Abstract translation: 本发明涉及包含酰胺衍生物或其药学上可接受的盐和酸性添加剂的药物组合物。 这种组合物由于长期保存后的稳定性的改善，适用于抑制癌细胞的生长。

公开(公告)号：WO2009002084A3

公开(公告)日：2009-02-26

申请号：PCT/KR2008003623

申请日：2008-06-25

Applicant: HANMI PHARM IND CO LTD ,  LEE CHANG HYUN ,  WOO JONG SOO ,  YI HONG GI ,  KIM KYEONG SOO ,  YIM HO TAEK

Inventor： LEE CHANG HYUN ,  WOO JONG SOO ,  YI HONG GI ,  KIM KYEONG SOO ,  YIM HO TAEK

IPC: A61K9/14 ,  A61K9/20

CPC classification number: A61K9/0056 ,  A61J3/10 ,  A61K9/2095 ,  B30B11/02 ,  B30B11/08 ,  B65B9/042 ,  B65B9/045

Abstract: A method and packaging machine for preparing rapidly disintegrating formulations for oral administration are disclosed. The present invention is characterized in that a powdery mixture including a pharmaceutically active ingredient and a sugar or a sugar alcohol powder is filled into a packaging material and, thereafter, the mixture, filled in the packaging material, is heated. The present invention can simply and economically prepare an oral formulation which undergoes rapid disintegration in the oral cavity and provides for high-quality administration to patients.

Abstract translation: 公开了用于制备用于口服给药的快速崩解制剂的方法和包装机。 本发明的特征在于将包含药物活性成分和糖或糖醇粉末的粉末混合物填充到包装材料中，然后将填充在包装材料中的混合物加热。 本发明可以简单且经济地制备在口腔中快速崩解并提供给患者高质量给药的口服制剂。

公开(公告)号：WO2014014150A1

公开(公告)日：2014-01-23

申请号：PCT/KR2012/005828

申请日：2012-07-20

Applicant: HANMI PHARM. CO., LTD. ,  SRINIVASAN, Shanmugam ,  KIM, Kyeong Soo ,  KIM, Yong Il ,  PARK, Jae Hyun ,  WOO, Jong Soo

Inventor： SRINIVASAN, Shanmugam ,  KIM, Kyeong Soo ,  KIM, Yong Il ,  PARK, Jae Hyun ,  WOO, Jong Soo

IPC: A61K31/351 ,  A61K31/185 ,  A61K47/40 ,  A61K9/24 ,  A61K9/22 ,  A61K9/20

CPC classification number: A61K9/2013 ,  A61K9/1617 ,  A61K9/2846 ,  A61K9/4891 ,  A61K31/7012

Abstract: Provided is a pharmaceutical composition comprising an antiviral neuraminidase inhibitor and a permeation enhancer with improved oral absorption and/or bioavailability, which can be useful in for preventing or treating viral infections, in particular, influenza A and B virus infections.

Abstract translation: 提供了包含抗病毒神经氨酸酶抑制剂和具有改善的口服吸收和/或生物利用度的渗透促进剂的药物组合物，其可用于预防或治疗病毒感染，特别是甲型和乙型流感病毒感染。

公开(公告)号：WO2012169733A1

公开(公告)日：2012-12-13

申请号：PCT/KR2012/003970

申请日：2012-05-18

Applicant: HANMI PHARM. CO., LTD. ,  KIM, Yong Il ,  KIM, Kyeong Soo ,  KIM, Jin Cheul ,  KIM, Yo Han ,  PARK, Jae Hyun ,  WOO, Jong Soo

Inventor： KIM, Yong Il ,  KIM, Kyeong Soo ,  KIM, Jin Cheul ,  KIM, Yo Han ,  PARK, Jae Hyun ,  WOO, Jong Soo

IPC: C07D401/12 ,  C07C69/604 ,  A61K31/517 ,  A61P35/00

CPC classification number: A61K47/44 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2031 ,  A61K9/2077 ,  A61K31/517 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36 ,  C07D401/12

Abstract: Disclosed is a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof and a non-metallic salt lubricant, which can be used as an effective cancer cell-growth inhibitor owing to its enhanced storage stability with no quality changes over time.

Abstract translation: 公开了一种药物组合物，其包含酰胺衍生物或其药学上可接受的盐和非金属盐润滑剂，其可以用作有效的癌细胞生长抑制剂，这是由于其增强的储存稳定性而随时间而没有质量变化。

公开(公告)号：WO2011155793A2

公开(公告)日：2011-12-15

申请号：PCT/KR2011/004271

申请日：2011-06-10

Applicant: HANMI HOLDINGS CO., LTD. ,  KIM, Yong Il ,  KIM, Kyeong Soo ,  JANG, Ki Young ,  KIM, Yo Han ,  PARK, Jae Hyun ,  WOO, Jong Soo

Inventor： KIM, Yong Il ,  KIM, Kyeong Soo ,  JANG, Ki Young ,  KIM, Yo Han ,  PARK, Jae Hyun ,  WOO, Jong Soo

IPC: C07D401/12 ,  C07D401/14 ,  A61K31/497 ,  A61P35/00

CPC classification number: A61K47/24 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2077 ,  A61K9/4858 ,  A61K31/497 ,  A61K31/517 ,  A61K47/12 ,  C07D401/12 ,  C07D401/14

Abstract: The present invention relates to a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof, and an acidic additive. This composition, owing to improved stability even after a long-term storage, is suitable for inhibiting the growth of cancer cells.

Abstract translation: 本发明涉及包含酰胺衍生物或其药学上可接受的盐和酸性添加剂的药物组合物。 这种组合物由于长期保存后的稳定性的改善，适用于抑制癌细胞的生长。

公开(公告)号：WO2010071336A2

公开(公告)日：2010-06-24

申请号：PCT/KR2009007484

申请日：2009-12-15

Applicant: KIM KYEONG-SOO ,  CHO HYO JE

Inventor： KIM KYEONG-SOO

IPC: B29B17/00 ,  C08J11/00

CPC classification number: B29B17/0026 ,  B29B2017/0094 ,  B29K2025/00 ,  C08J11/08 ,  C08J2325/06 ,  Y02W30/62 ,  Y02W30/701

Abstract: The present invention relates to a method for waste EPS recycling and equipment for same. The recycling method comprises a solvent preparation step wherein a solution containing dimethyl glutarate with concentration of 60% or higher, dimethyl adipate with concentration of 10-30%, and dimethyl succinate with a concentration of 10-30%; a step wherein waste EPS is crushed; a step wherein the crushed EPS is dissolved and air and PS are separated; a step wherein the separated PS is cooled and gelled; a step wherein the gelled PS is placed in water to remove any solvent remaining in PS; a step wherein the washed PS is pressed; a step in which the pressed PS is extruded; a step wherein secondary residual solvent is removed from the extruded PS; and a step wherein cut PS is dried. The solvent is heated at 30-70°C in order for said EPS to undergo smooth dissolution in said solvent, said dissolved PS is cooled to between -10°C and 10°C for gelation; said gelled PS is placed into water to wash off solvent remaining in the PS, washing water and the solvent generated following water washing are separated based on their different specific gravities to reuse the solvent and water, and the PS extruded from the step for extruding said PS is immediately placed in water and washed, and the solvent and water generated by such washing are separated by the centrifugal separation method based on their differences in the specific gravity and then reused. The apparatus used for this, for example, comprises an addition device (5) that is installed inside a vehicle and accommodates waste EPS, a crushing device (1) that is installed inside the addition device (5) and has a crushing blade (8), a solvent tank (2) that accommodates waste EPS crushed in the crushing device (1) and contains a solvent used to dissolve the waste EPS, and an agitator (3) that is installed inside the solvent tank (2) and agitates waste EPS with a motor (6).

Abstract translation: 废物EPS回收方法及其设备 回收方法包括溶剂制备步骤，其中包含浓度为60％或更高的戊二酸二甲酯，浓度为10-30％的己二酸二甲酯和浓度为10-30％的琥珀酸二甲酯的溶液; 废物EPS被压碎的步骤; 破碎的EPS被溶解并且空气和PS被分离的步骤; 分离的PS冷却并凝胶的步骤; 将凝胶化的PS置于水中以除去残留在PS中的任何溶剂的步骤; 压制清洗过的PS的步骤; 挤压PS挤出的步骤; 从挤出的PS中除去二次残留溶剂的步骤; 和切割PS干燥的步骤。 将溶剂在30-70℃加热以使所述EPS在所述溶剂中平稳溶解，将所述溶解的PS冷却至-10℃至10℃之间用于凝胶化; 将所述凝胶状PS放入水中以洗掉残留在PS中的溶剂，根据洗涤水和水洗后产生的溶剂根据其不同的比重分离以重新使用溶剂和水，从所述挤出步骤挤出的PS PS立即置于水中并洗涤，并且通过这种洗涤产生的溶剂和水根据其比重差异通过离心分离方法分离，然后重新使用。 为此所使用的设备例如包括安装在车辆内部并容纳废弃EPS的添加装置（5），安装在添加装置（5）内并具有破碎刀片（8）的破碎装置（1） ），容纳在粉碎装置（1）中粉碎的废弃EPS的溶剂罐（2），该溶剂罐含有用于溶解废弃EPS的溶剂，搅拌装置（3）设置在溶剂罐（2）的内部，搅拌废弃物 带电机的EPS（6）。

公开(公告)号：WO2013012199A1

公开(公告)日：2013-01-24

申请号：PCT/KR2012/005506

申请日：2012-07-11

Applicant: HANMI PHARM. CO., LTD. ,  KIM, Yong Il ,  KIM, Dong Ho ,  KWON, Taek Kwan ,  KIM, Kyeong Soo ,  PARK, Jae Hyun ,  WOO, Jong Soo

Inventor： KIM, Yong Il ,  KIM, Dong Ho ,  KWON, Taek Kwan ,  KIM, Kyeong Soo ,  PARK, Jae Hyun ,  WOO, Jong Soo

IPC: A61K9/48 ,  A61K31/47 ,  A61K31/4704 ,  C07D215/18

CPC classification number: A61K9/4808 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/4816 ,  A61K31/47 ,  A61K31/473 ,  A61K31/495 ,  A61K31/4965 ,  C07D215/12 ,  C07D295/06 ,  C07D295/08 ,  A61K2300/00

Abstract: Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: (1) a Montelukast layer comprising montelukast or a pharmaceutically acceptable salt thereof; and (2) a Levocetirizine layer comprising levocetirizine or a pharmaceutically acceptable salt thereof; and a method for the preparation thereof. The capsule formulation according to the present invention can completely separate two active ingredients, thereby minimizing the reactivity between them and improving product stability against aging effects, and thus, can optimize the therapeutic effects.

Abstract translation: 公开了一种用于预防或治疗过敏性鼻炎和哮喘的胶囊制剂，其包含两个单独的层：（1）包含孟鲁司特或其药学上可接受的盐的蒙特卡斯特层; 和（2）包含左西替利嗪或其药学上可接受的盐的左西替利嗪层; 及其制备方法。 根据本发明的胶囊制剂可以完全分离两种活性成分，从而最小化它们之间的反应性并提高产品对抗老化作用的稳定性，从而可以优化治疗效果。